Cargando…

Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines

Chemotherapy has been a mainstay in cancer treatment for many years. Despite some success, the cure rate with chemotherapy remains unsatisfactory in some types of cancers, and severe side effects from these treatments are a concern. Recently, understanding of the dynamic interplay between the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Weir, Genevieve M., Liwski, Robert S., Mansour, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759189/
https://www.ncbi.nlm.nih.gov/pubmed/24212948
http://dx.doi.org/10.3390/cancers3033114
_version_ 1782477220354195456
author Weir, Genevieve M.
Liwski, Robert S.
Mansour, Marc
author_facet Weir, Genevieve M.
Liwski, Robert S.
Mansour, Marc
author_sort Weir, Genevieve M.
collection PubMed
description Chemotherapy has been a mainstay in cancer treatment for many years. Despite some success, the cure rate with chemotherapy remains unsatisfactory in some types of cancers, and severe side effects from these treatments are a concern. Recently, understanding of the dynamic interplay between the tumor and immune system has led to the development of novel immunotherapies, including cancer vaccines. Cancer vaccines have many advantageous features, but their use has been hampered by poor immunogenicity. Many developments have increased their potency in pre-clinical models, but cancer vaccines continue to have a poor clinical track record. In part, this could be due to an inability to effectively overcome tumor-induced immune suppression. It had been generally assumed that immune-stimulatory cancer vaccines could not be used in combination with immunosuppressive chemotherapies, but recent evidence has challenged this dogma. Chemotherapies could be used to condition the immune system and tumor to create an environment where cancer vaccines have a better chance of success. Other types of immunotherapies could also be used to modulate the immune system. This review will discuss how immune modulation by chemotherapy or immunotherapy could be used to bolster the effects of cancer vaccines and discuss the advantages and disadvantages of these treatments.
format Online
Article
Text
id pubmed-3759189
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37591892013-09-04 Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines Weir, Genevieve M. Liwski, Robert S. Mansour, Marc Cancers (Basel) Review Chemotherapy has been a mainstay in cancer treatment for many years. Despite some success, the cure rate with chemotherapy remains unsatisfactory in some types of cancers, and severe side effects from these treatments are a concern. Recently, understanding of the dynamic interplay between the tumor and immune system has led to the development of novel immunotherapies, including cancer vaccines. Cancer vaccines have many advantageous features, but their use has been hampered by poor immunogenicity. Many developments have increased their potency in pre-clinical models, but cancer vaccines continue to have a poor clinical track record. In part, this could be due to an inability to effectively overcome tumor-induced immune suppression. It had been generally assumed that immune-stimulatory cancer vaccines could not be used in combination with immunosuppressive chemotherapies, but recent evidence has challenged this dogma. Chemotherapies could be used to condition the immune system and tumor to create an environment where cancer vaccines have a better chance of success. Other types of immunotherapies could also be used to modulate the immune system. This review will discuss how immune modulation by chemotherapy or immunotherapy could be used to bolster the effects of cancer vaccines and discuss the advantages and disadvantages of these treatments. Molecular Diversity Preservation International (MDPI) 2011-08-05 /pmc/articles/PMC3759189/ /pubmed/24212948 http://dx.doi.org/10.3390/cancers3033114 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Weir, Genevieve M.
Liwski, Robert S.
Mansour, Marc
Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
title Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
title_full Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
title_fullStr Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
title_full_unstemmed Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
title_short Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
title_sort immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759189/
https://www.ncbi.nlm.nih.gov/pubmed/24212948
http://dx.doi.org/10.3390/cancers3033114
work_keys_str_mv AT weirgenevievem immunemodulationbychemotherapyorimmunotherapytoenhancecancervaccines
AT liwskiroberts immunemodulationbychemotherapyorimmunotherapytoenhancecancervaccines
AT mansourmarc immunemodulationbychemotherapyorimmunotherapytoenhancecancervaccines